Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease […]

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026

Over the past 40 years, treatment for pulmonary arterial hypertension (PAH) has changed dramatically. What was once considered a disease with very few treatment options is now managed with a growing range of therapies that help people live longer and enjoy a better quality of life. A review recently published in Circulation looks back at

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026 Read Post »

Web-based survey explores patient perspectives on palliative care in pulmonary arterial hypertension in the US, Pulmonary Circulation, June 24, 2026

A US web-based survey involving 200 respondents across 42 states was completed Sept–Oct 2023. The survey explored how patients with pulmonary arterial hypertension (PAH) understand and experience palliative care — which can be offered alongside standard treatment to ease symptoms and improve quality of life, but is underused and often misunderstood. Most respondents equated palliative

Web-based survey explores patient perspectives on palliative care in pulmonary arterial hypertension in the US, Pulmonary Circulation, June 24, 2026 Read Post »

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026

This “How I Do It” article addresses a practical question now facing pulmonary arterial hypertension (PAH) clinicians: as sotatercept gets added to background combination treatment, some patients on prostacyclin therapy show sustained improvement — raising the question of whether their prostacyclin dose can be safely reduced. The challenge is that standard monitoring tools (functional class,

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026 Read Post »

Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT

Pulmonary hypertension treatments continue to evolve and one very promising advancing treatment option is inhaled therapy which delivers medication directly to the lungs. The webinar speakers will discuss the current landscape and future of inhaled therapies in pulmonary hypertension, including:• Currently approved inhaled therapies.• Key differences between inhaled treatment options and the conditions they manage,

Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT Read Post »

A roundtable of US pulmonologists discusses sotatercept, de-escalation, and the limits of upfront therapy for pulmonary arterial hypertension, HCP Live, June 22, 2026

An HCPLive roundtable of pulmonologists from UCLA, Cedars-Sinai, and community practices discussed optimizing pulmonary arterial hypertension management. Key points: Treatment sequencing: Upfront dual oral combination therapy (ERA + PDE5 inhibitor) remains standard for non-high-risk patients, though sotatercept hasn’t formally displaced it despite growing clinical interest. An Italian study cited at the roundtable found about a

A roundtable of US pulmonologists discusses sotatercept, de-escalation, and the limits of upfront therapy for pulmonary arterial hypertension, HCP Live, June 22, 2026 Read Post »

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026

French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. They found that both treatments lowered the resistance in the blood vessels of the lungs, making it easier for blood to flow. However, the treatments worked

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026 Read Post »

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension

New study aims to see how 24 weeks of triple therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept, affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension. SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up.

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension Read Post »

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026

Researchers from China have traced the remarkable 30-year evolution of pulmonary arterial hypertension treatment, from a disease with no effective options to one on the cusp of a potential cure. What was once described as the “cancer of cardiovascular diseases” — with a median survival of just 2.8 years after diagnosis — has become a

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026 Read Post »

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026

New pooled data presented in the form of a scientific poster at the American Thoracic Society 2026 International Conference in Orlando suggests that sotatercept may significantly reduce morbidity and mortality risks in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a particularly challenging population to treat. The analysis combined data from three phase

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026 Read Post »

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026

Researchers from Canada have published a review which summarizes recently established and emerging signalling pathways that may influence the next generation of targeted pulmonary arterial hypertension therapies. They note that the therapeutic landscape for this condition is moving towards mechanism-based approaches with the potential to alter the course of the disease. In particular, the transforming

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026 Read Post »

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026

Despite the comprehensive, evidence-based guidance offered by current international guidelines on the management of pulmonary hypertension, clinicians frequently encounter situations where the correct diagnosis or the most appropriate treatment remains uncertain. Methods A panel of pulmonary hypertension experts identified ten real-world diagnostic and management dilemmas during 2024–2025. For each, the available evidence was reviewed and

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026 Read Post »

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026

The right heart catheter – also known as cardiac catheterisation, and abbreviated as RHC –is considered the “gold standard’ test to diagnose pulmonary arterial hypertension, and at follow up to monitor progress of the condition and efficacy of treatments. In this video Dr Charlie Elliott, from the Sheffield Pulmonary Vascular Disease Unit, who has performed

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026 Read Post »

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30

One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30 Read Post »

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026

To date sotatercept has only been studied in patients with prevalent pulmonary arterial hypertension receiving stable background therapy, not as part of the initial treatment regimen in newly diagnosed patients. A case report, published recently on the ERJ Open Research, describes a 25-year-old woman who developed severe high-risk idiopathic pulmonary arterial hypertension (IPAH) shortly after

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026 Read Post »

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026

The Phase 2 CADENCE randomised controlled trial tested sotatercept in patients with combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction (CpcPH-HFpEF) — a serious condition with high mortality and no proven treatments (Group 2 WHO pulmonary hypertension classification). 164 patients received either sotatercept (at one of two doses) or placebo

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026 Read Post »

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026

Since sotatercept received Food and Drug Administration (FDA) approval for pulmonary arterial hypertension in March 2024, knowing when and how to use it has become an essential part of managing this serious condition — so say the authors of a recently published article in CHEST, who offer a practical guide for clinicians navigating this new

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026 Read Post »

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026

This review covers the full clinical picture of pulmonary arterial hypertension (PAH) — from its pathophysiology and diagnosis through to current and emerging treatments. Understanding the Disease Pulmonary arterial hypertension is driven by progressive structural remodelling of the pulmonary arteries, creating a vicious cycle of vasoconstriction, inflammation, and uncontrolled cell growth that ultimately leads to

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026 Read Post »

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026

A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026 Read Post »

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026

A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements are intended to support physicians

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026 Read Post »

TRANSLATE »
Scroll to Top